Lessons from the Pacific programme to eliminate lymphatic filariasis: a case study of 5 countries.
Identifieur interne : 002E31 ( PubMed/Corpus ); précédent : 002E30; suivant : 002E32Lessons from the Pacific programme to eliminate lymphatic filariasis: a case study of 5 countries.
Auteurs : Clare Huppatz ; Corinne Capuano ; Kevin Palmer ; Paul M. Kelly ; David N. DurrheimSource :
- BMC infectious diseases [ 1471-2334 ] ; 2009.
English descriptors
- KwdEn :
- MESH :
- geographic , epidemiology : Polynesia, Samoa, Tonga, Vanuatu.
- epidemiology : Elephantiasis, Filarial.
- prevention & control : Elephantiasis, Filarial.
- Health Surveys, Humans.
Abstract
Lymphatic Filariasis (LF) is an important Neglected Tropical Disease, being a major cause of disability worldwide. The Global Programme to Eliminate Lymphatic Filariasis aims to eliminate LF as a public health problem by the year 2020, primarily through repeated Mass Drug Administration (MDA). The Pacific region programme commenced in 1999. By June 2007, five of the eleven countries classified as endemic had completed five MDA campaigns and post-MDA prevalence surveys to assess their progress. We review available programme data and discuss their implications for other LF elimination programs in developing countries.
DOI: 10.1186/1471-2334-9-92
PubMed: 19523192
Links to Exploration step
pubmed:19523192Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Lessons from the Pacific programme to eliminate lymphatic filariasis: a case study of 5 countries.</title><author><name sortKey="Huppatz, Clare" sort="Huppatz, Clare" uniqKey="Huppatz C" first="Clare" last="Huppatz">Clare Huppatz</name><affiliation><nlm:affiliation>Hunter New England Population Health Unit, New South Wales Health, Wallsend, Australia. clarehuppatz@yahoo.com</nlm:affiliation></affiliation></author><author><name sortKey="Capuano, Corinne" sort="Capuano, Corinne" uniqKey="Capuano C" first="Corinne" last="Capuano">Corinne Capuano</name></author><author><name sortKey="Palmer, Kevin" sort="Palmer, Kevin" uniqKey="Palmer K" first="Kevin" last="Palmer">Kevin Palmer</name></author><author><name sortKey="Kelly, Paul M" sort="Kelly, Paul M" uniqKey="Kelly P" first="Paul M" last="Kelly">Paul M. Kelly</name></author><author><name sortKey="Durrheim, David N" sort="Durrheim, David N" uniqKey="Durrheim D" first="David N" last="Durrheim">David N. Durrheim</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:19523192</idno><idno type="pmid">19523192</idno><idno type="doi">10.1186/1471-2334-9-92</idno><idno type="wicri:Area/PubMed/Corpus">002E31</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002E31</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Lessons from the Pacific programme to eliminate lymphatic filariasis: a case study of 5 countries.</title><author><name sortKey="Huppatz, Clare" sort="Huppatz, Clare" uniqKey="Huppatz C" first="Clare" last="Huppatz">Clare Huppatz</name><affiliation><nlm:affiliation>Hunter New England Population Health Unit, New South Wales Health, Wallsend, Australia. clarehuppatz@yahoo.com</nlm:affiliation></affiliation></author><author><name sortKey="Capuano, Corinne" sort="Capuano, Corinne" uniqKey="Capuano C" first="Corinne" last="Capuano">Corinne Capuano</name></author><author><name sortKey="Palmer, Kevin" sort="Palmer, Kevin" uniqKey="Palmer K" first="Kevin" last="Palmer">Kevin Palmer</name></author><author><name sortKey="Kelly, Paul M" sort="Kelly, Paul M" uniqKey="Kelly P" first="Paul M" last="Kelly">Paul M. Kelly</name></author><author><name sortKey="Durrheim, David N" sort="Durrheim, David N" uniqKey="Durrheim D" first="David N" last="Durrheim">David N. Durrheim</name></author></analytic><series><title level="j">BMC infectious diseases</title><idno type="eISSN">1471-2334</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Elephantiasis, Filarial (epidemiology)</term><term>Elephantiasis, Filarial (prevention & control)</term><term>Health Surveys</term><term>Humans</term><term>Polynesia (epidemiology)</term><term>Samoa (epidemiology)</term><term>Tonga (epidemiology)</term><term>Vanuatu (epidemiology)</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Polynesia</term><term>Samoa</term><term>Tonga</term><term>Vanuatu</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Health Surveys</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Lymphatic Filariasis (LF) is an important Neglected Tropical Disease, being a major cause of disability worldwide. The Global Programme to Eliminate Lymphatic Filariasis aims to eliminate LF as a public health problem by the year 2020, primarily through repeated Mass Drug Administration (MDA). The Pacific region programme commenced in 1999. By June 2007, five of the eleven countries classified as endemic had completed five MDA campaigns and post-MDA prevalence surveys to assess their progress. We review available programme data and discuss their implications for other LF elimination programs in developing countries.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19523192</PMID><DateCreated><Year>2009</Year><Month>06</Month><Day>29</Day></DateCreated><DateCompleted><Year>2009</Year><Month>07</Month><Day>10</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2334</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><PubDate><Year>2009</Year><Month>Jun</Month><Day>12</Day></PubDate></JournalIssue><Title>BMC infectious diseases</Title><ISOAbbreviation>BMC Infect. Dis.</ISOAbbreviation></Journal><ArticleTitle>Lessons from the Pacific programme to eliminate lymphatic filariasis: a case study of 5 countries.</ArticleTitle><Pagination><MedlinePgn>92</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1471-2334-9-92</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Lymphatic Filariasis (LF) is an important Neglected Tropical Disease, being a major cause of disability worldwide. The Global Programme to Eliminate Lymphatic Filariasis aims to eliminate LF as a public health problem by the year 2020, primarily through repeated Mass Drug Administration (MDA). The Pacific region programme commenced in 1999. By June 2007, five of the eleven countries classified as endemic had completed five MDA campaigns and post-MDA prevalence surveys to assess their progress. We review available programme data and discuss their implications for other LF elimination programs in developing countries.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Reported MDA coverage and results from initial surveys and post-MDA surveys of LF using the immunochromatographic test (ICT) from these five Pacific Island countries (Tonga, Niue, Vanuatu, Samoa and Cook Islands) were analysed to provide an understanding of their quality and programme progress towards LF elimination. Denominator data reported by each country programme for 2001 was compared to official sources to assess the accuracy of MDA coverage data.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Initial survey results from these five countries revealed an ICT prevalence of between 2.7 and 8.6 percent in individuals tested prior to commencement of the programme. Country MDA coverage results varied depending on the source of denominator data. Of the five countries in this case study, three countries (Tonga, Niue and Vanuatu) reached the target prevalence of <1% antigenaemia following five rounds of MDA. However, endpoint data could not be reliably compared to baseline data as survey methodology varied.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Accurate and representative baseline and post-campaign prevalence data is crucial for determining program effectiveness and the factors contributing to effectiveness. This is emphasised by the findings of this case study. While three of the five Pacific countries reported achieving the target prevalence of <1% antigenaemia, limitations in the data preclude identification of key determinants of this achievement.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huppatz</LastName><ForeName>Clare</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Hunter New England Population Health Unit, New South Wales Health, Wallsend, Australia. clarehuppatz@yahoo.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Capuano</LastName><ForeName>Corinne</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Palmer</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Kelly</LastName><ForeName>Paul M</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><LastName>Durrheim</LastName><ForeName>David N</ForeName><Initials>DN</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>06</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Infect Dis</MedlineTA><NlmUniqueID>100968551</NlmUniqueID><ISSNLinking>1471-2334</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Trop Med Int Health. 2000 May;5(5):359-63</RefSource><PMID Version="1">10886800</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trop Med Int Health. 2005 Jun;10(6):567-73</RefSource><PMID Version="1">15941420</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Bull World Health Organ. 2007 Jun;85(6):493-8</RefSource><PMID Version="1">17639248</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trop Med Int Health. 2006 Jun;11(6):862-8</RefSource><PMID Version="1">16772008</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trans R Soc Trop Med Hyg. 2007 May;101(5):445-53</RefSource><PMID Version="1">17125809</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Filaria J. 2007 Mar 29;6:4</RefSource><PMID Version="1">17391538</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Adv Parasitol. 2006;61:395-441</RefSource><PMID Version="1">16735170</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parasitology. 1996 Apr;112 ( Pt 4):409-28</RefSource><PMID Version="1">8935952</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trop Med Int Health. 2004 Jun;9(6):702-9</RefSource><PMID Version="1">15189460</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parasitol Today. 1997 Oct;13(10):401-4</RefSource><PMID Version="1">15275155</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Bull World Health Organ. 1997;75(6):491-503</RefSource><PMID Version="1">9509621</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Infect Dis. 2004 Apr;4(4):223-34</RefSource><PMID Version="1">15050941</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Filaria J. 2007 Jan 01;6:1</RefSource><PMID Version="1">17196113</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Filaria J. 2006 Aug 16;5:10</RefSource><PMID Version="1">16914040</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006306" MajorTopicYN="N">Health Surveys</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011114" MajorTopicYN="N" Type="Geographic">Polynesia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018947" MajorTopicYN="N" Type="Geographic">Samoa</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014058" MajorTopicYN="N" Type="Geographic">Tonga</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009514" MajorTopicYN="N" Type="Geographic">Vanuatu</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC2702370</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>06</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>6</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>6</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>7</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19523192</ArticleId><ArticleId IdType="pii">1471-2334-9-92</ArticleId><ArticleId IdType="doi">10.1186/1471-2334-9-92</ArticleId><ArticleId IdType="pmc">PMC2702370</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E31 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002E31 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:19523192
|texte= Lessons from the Pacific programme to eliminate lymphatic filariasis: a case study of 5 countries.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:19523192" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |